Pharsight

Gilenya patents expiration

GILENYA's oppositions filed in EPO
GILENYA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324283 NOVARTIS Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol
Mar, 2026

(1 year, 11 months from now)

US8324283

(Pediatric)

NOVARTIS Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol
Sep, 2026

(2 years from now)

US9187405 NOVARTIS S1P receptor modulators for treating relasping-remitting multiple sclerosis
Jun, 2027

(3 years from now)

US10543179 NOVARTIS Dosage regimen of an S1P receptor modulator
Dec, 2027

(3 years from now)

US9187405

(Pediatric)

NOVARTIS S1P receptor modulators for treating relasping-remitting multiple sclerosis
Dec, 2027

(3 years from now)

US9592208 NOVARTIS Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
Mar, 2032

(8 years from now)

US9592208

(Pediatric)

NOVARTIS Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
Sep, 2032

(8 years from now)

Gilenya is owned by Novartis.

Gilenya contains Fingolimod Hydrochloride.

Gilenya has a total of 7 drug patents out of which 0 drug patents have expired.

Gilenya was authorised for market use on 21 September, 2010.

Gilenya is available in capsule;oral dosage forms.

Gilenya can be used as treatment of multiple sclerosis in the pediatric patient population with 0.25 mg fingolimod, treatment of relapsing remitting multiple sclerosis by determining varicella zoster virus (vzv) status and vaccinating prior to commencing treatment, treatment of relapsing-remitting sclerosis (ms).

The generics of Gilenya are possible to be released after 30 September, 2032.

Drugs and Companies using FINGOLIMOD HYDROCHLORIDE ingredient

Market Authorisation Date: 21 September, 2010

Treatment: Treatment of relapsing-remitting sclerosis (ms); Treatment of relapsing remitting multiple sclerosis by determining varicella zoster virus (vzv) status and vaccinating prior to commencing treatment; T...

Dosage: CAPSULE;ORAL

How can I launch a generic of GILENYA before it's drug patent expiration?
More Information on Dosage

GILENYA family patents

Family Patents